These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 21138823)

  • 1. Ticagrelor: a novel oral antiplatelet agent.
    Huang NS; Master HH; Fusco JA; Park ZH
    Consult Pharm; 2010 Nov; 25(11):745-55. PubMed ID: 21138823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of the 2010 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting regarding ticagrelor.
    Gaglia MA; Waksman R
    Circulation; 2011 Feb; 123(4):451-6. PubMed ID: 21242480
    [No Abstract]   [Full Text] [Related]  

  • 3. Ideal antiplatelet therapy for coronary artery disease: focus on adenosine diphosphate receptor inhibitors.
    Chandrasekar S; Loomba R; Shah P; Arora R
    Am J Ther; 2013; 20(4):337-43. PubMed ID: 21519219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ticagrelor for the treatment of arterial thrombosis.
    Gurbel PA; Kereiakes DJ; Tantry US
    Expert Opin Pharmacother; 2010 Sep; 11(13):2251-9. PubMed ID: 20707759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ticagrelor: oral reversible P2Y(12) receptor antagonist for the management of acute coronary syndromes.
    Cheng JW
    Clin Ther; 2012 Jun; 34(6):1209-20. PubMed ID: 22521881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ticagrelor: from discovery to Phase III clinical trial.
    Siller-Matula JM; Jilma B
    Future Cardiol; 2010 Nov; 6(6):753-64. PubMed ID: 21142630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ADP-receptor inhibitors in the perioperative period: the good, the bad, and the ugly.
    Oprea AD; Popescu WM
    J Cardiothorac Vasc Anesth; 2013 Aug; 27(4):779-95. PubMed ID: 23648080
    [No Abstract]   [Full Text] [Related]  

  • 8. Prasugrel for the treatment of coronary thrombosis: a review of pharmacological properties, indications for use and future development.
    Tomasello SD; Tello-Montoliu A; Angiolillo DJ
    Expert Opin Investig Drugs; 2011 Jan; 20(1):119-33. PubMed ID: 21143003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model.
    Ravnefjord A; Weilitz J; Emanuelsson BM; van Giezen JJ
    Thromb Res; 2012 Oct; 130(4):622-8. PubMed ID: 22909827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual thienopyridine low-response to clopidogrel and prasugrel in a patient with STEMI, cardiogenic shock and early stent thrombosis is overcome by ticagrelor.
    Orban M; Riegger J; Joner M; Tada T; Okrojek R; Hausleiter J; Kastrati A; Massberg S; Sibbing D
    Platelets; 2012; 23(5):395-8. PubMed ID: 22671583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fresh from the pipeline. Ticagrelor.
    Huber K; Hamad B; Kirkpatrick P
    Nat Rev Drug Discov; 2011 Apr; 10(4):255-6. PubMed ID: 21455230
    [No Abstract]   [Full Text] [Related]  

  • 12. Ticagrelor (Brilinta)--better than clopidogrel (Plavix)?
    Med Lett Drugs Ther; 2011 Sep; 53(1372):69-70. PubMed ID: 21897348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ticagrelor for the treatment of peripheral arterial disease.
    Chong AY; So DY
    Expert Opin Investig Drugs; 2014 Dec; 23(12):1737-43. PubMed ID: 25376000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "Conversations in cardiology": How do you pick the best antiplatelet drug--clopidogrel, prasugrel, ticagrelor for your PCI patient?
    Kern MJ
    Catheter Cardiovasc Interv; 2012 Feb; 79(2):255-62. PubMed ID: 22271555
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors.
    Storey RF
    Thromb Haemost; 2011 May; 105 Suppl 1():S75-81. PubMed ID: 21479343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
    Kowalczyk M; Banach M; Mikhailidis DP; Hannam S; Rysz J
    Med Sci Monit; 2009 Dec; 15(12):MS24-30. PubMed ID: 19946242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mortality benefit in PLATO cannot be explained by antiplatelet properties of ticagrelor.
    Serebruany VL
    Cardiology; 2010; 117(3):231-3. PubMed ID: 21212672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comprehensive comparative review of adenosine diphosphate receptor antagonists.
    Oh EY; Abraham T; Saad N; Rapp JH; Vastey FL; Balmir E
    Expert Opin Pharmacother; 2012 Feb; 13(2):175-91. PubMed ID: 22216937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety profile and bleeding risk of ticagrelor compared with clopidogrel.
    May CH; Lincoff AM
    Expert Opin Drug Saf; 2012 Nov; 11(6):959-67. PubMed ID: 22950441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ticagrelor: the silence of the platelets.
    Laine M; Paganelli F; Bonello L
    Expert Opin Pharmacother; 2013 Feb; 14(2):151-3. PubMed ID: 23294190
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.